AGP Executive Report
Last update: 9 hours agoSynthetic Food Safety: A peer-reviewed study warns “synbio milk” made by Perfect Day contains 93 uncharacterized compounds and 236 fungal proteins never tested for human consumption, with Italy moving to ban synthetic food products. Cognitive Health & Diet: Monash University research links higher ultra-processed food intake to worse visual attention and slower mental processing speed, even among people otherwise eating “healthy” diets. Cancer Care Advances: Roche’s atezolizumab plus chemotherapy wins FDA priority review for adjuvant stage III dMMR/MSI-H colon cancer, while new EHA data highlight a durable MRD-negative response approach in IDH1+ AML. Parkinson’s Drug Setback: Bial discontinues pariceract after Phase 2b ACTIVATE failed to meet primary and key secondary endpoints in GBA1-associated Parkinson disease. Heart Health Access: Global Heart Hub reports women often delay seeking care for heart symptoms, contributing to recognition and diagnosis gaps. Oral Cancer Prevention: Spain’s dentists’ college urges regular check-ups, noting early detection can push survival above 90%. Rare Disease Policy: UK MHRA’s rare disease framework is under pressure to go further, with calls for stronger incentives similar to US priority review vouchers. Drug Pricing Pressure in Germany: Germany’s health minister says drugmakers won’t be exempt from cost cuts despite investment concerns.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.